SEHK:2269Life Sciences
WuXi Biologics (SEHK:2269) Margin Improvement Challenges Bearish Profitability Narratives
WuXi Biologics (Cayman) (SEHK:2269) has reported its FY 2025 numbers with second half revenue of about C¥11.8b and basic EPS of C¥0.64, supported by trailing twelve month revenue of roughly C¥21.8b and EPS of C¥1.22 that sit alongside a 46.3% year over year earnings gain. The company has seen revenue move from around C¥18.7b to C¥21.8b on a trailing basis, while trailing EPS has shifted from C¥0.82 to C¥1.22, setting up a story where rising profit levels are paired with healthier margins that...